Sharp 2009b.

Clinical features and settings	Study period: n.r. Patient population: 23 patients with neuroblastoma. Consecutive series: n.r. Diagnostic work‐up: n.r. Time spans between symptoms and index test, between symptoms and reference standard and between index test and reference standard: n.r. Treatment between index test and reference standard: n.r.
Participants	Included patients: 23 patients with neuroblastoma. Median age: n.r. Sex distribution: n.r. INSS stage: n.r.
Study design	n.r.
Target condition and reference standard(s)	Target condition: n.r. Reference standard: n.r.
Index and comparator tests	Index test: ¹²³I‐MIBG SPECT/CT. Radiofarmacon: ¹²³I‐MIBG. Dose: 0.14 mCi/kg. Equipment: two different SPECT/CT scanners A and B (with diagnostic CT unit), details n.r. Acquisition protocol: WB planar MIBG scintigraphy, SPECT, and co‐registered low‐dose CT imaging Acquisition time: n.r. Acquisition duration: n.r. Interfering medication: n.r. Thyroid prophylaxis: n.r. Positive test result: foci of uptake. Number and expertise of observers: n.r. Interobserver concordance: n.r.
Follow‐up	n.r.
Notes	Not published in full‐text (as of 2009), but presented at the SIOP conference 2012. Results n.r. for ¹²³I‐MIBG scans at first diagnosis separately from the ¹²³I‐MIBG scans during follow‐up. We did not get contact with the authors.